Why the study?
Does thin-strut CoCr-DCS improve safety and efficacy compared to SS-DCS and BMS in high bleeding risk patients treated with 30 days of DAPT?
Does thin-strut CoCr-DCS improve safety and efficacy compared to SS-DCS and BMS in high bleeding risk patients treated with 30 days of DAPT?
In high bleeding risk patients receiving 1 month of DAPT, a new thin-strut polymer-free Biolimus-A9 coated stent was non-inferior for safety compared to SS-DCS and superior for efficacy compared to BMS at 1 year.
Answers are grounded in this paper and cite their sources.
Supports short DAPT with thin-strut CoCr-DCS in HBR patients; leaves open confirmation in randomized trials.
The new thin-strut CoCr-DCS proved non-inferior to the SS-DCS for safety, and superior to the BMS for efficacy in HBR patients treated with 30 days of DAPT.
No takes yet. Share an insight, caveat, or question.
Eberli et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: